News for Healthier Living

Penn study finds taking semaglutide for weight management does not increase risk of depression or suicidal behavior in people without known major psychopathology

Taking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania published this week in JAMA Internal Medicine. Both the Food and Drug Administration (FDA) and the European Medicines Agency are actively monitoring the psychiatric safety of semaglutide and similar medications after post marketing surveillance reports of depression, suicidal thoughts (ideation), and suicidal behavior in patients taking the drugs for the management of type 2 diabetes or obesity.

September 3, 2024


November 21 2025

November 20 2025

November 19 2025

November 18 2025

November 17 2025

November 16 2025

November 15 2025

November 14 2025

November 13 2025

November 12 2025

November 11 2025

November 10 2025

November 9 2025

November 8 2025

November 7 2025